News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

International Stem Cell Corporation Announces Positive R&D And Business Results For First Quarter 2014


5/13/2014 10:15:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARLSBAD, CA--(Marketwired - May 13, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update and announced financial results and for the three months ended March 31, 2014.

"Obtaining clarity from the FDA on our Parkinson's Disease program allows us to substantially lower the risk of unforeseen regulatory issues which could delay the program. By building the FDA's feedback into our plans, we will be able to prepare a stronger IND submission with an increased chance of a positive review," said Dr. Andrey Semechkin, the Company's CEO and Co-Chairman.

"On the commercial side, on a year over year basis, top-line revenues have grown for seven consecutive quarters, confirming that our subsidiaries are executing on their business plans and are on the right track. Looking forward to the rest of 2014, we see no reason why this growth should not continue; although we expect our cash burn to increase compared with last year as we push to complete our pre-clinical work and IND submission," concluded Dr. Semechkin.

Q1 2014 Highlights:

  • Held a pre-IND meeting with the U.S. Food and Drug Administration (FDA) clarifying the path to IND approval for ISCO's novel neural stem cell treatment for Parkinson's Disease (PD).
  • Announced positive three month data from the ongoing IND-enabling pharmacology/toxicology primate study demonstrating that a majority of the animals exhibit significant improvement in parkinsonism, including a return of many normal behaviors.
  • Revenues were up 28% year-over-year to $1.65 million for the three months ended March 31, 2014. Lifeline Cell Technologies (LCT) revenues were up 33% to $846,000. Lifeline Skin Care (LSC) revenues were up 24% to $803,000. Gross margin was 73.0% compared with 74.0% for the three months ended March 31, 2013.

Three Months Ended March 31, 2014

Revenue for the three months ended March 31, 2014, totaled $1.65 million, compared to $1.29 million for the three months ended March 31, 2013. LCT contributed $846,000 or 51% of total revenue for the three months ended March 31, 2014, compared to $635,000 or 49% for the three months ended March 31, 2013. LSC's revenue of $803,000 for the three months ended March 31, 2014 accounted for 49% of total revenue, compared to $650,000 or 51% of total revenue for the three months ended March 31, 2013. Cost of sales for the three months ended March 31, 2014 was $439,000 or 27% of revenue, compared to $334,000 or 26% of revenue for the three months ended March 31, 2013.

Research and development expenses were $958,000 for the three months ended March 31, 2014, compared to $721,000 for the same period in 2013. The increase of $237,000 or 33% is primarily due to increased stem cell line research and testing expenses.

Selling and marketing expenses for the three months ended March 31, 2014 were $669,000, reflecting an increase of $158,000 or 31%, as compared to $511,000 for the three months ended March 31, 2013. The increase in spending was primarily due to increased employee-related spending, consulting expenses, and expenses for marketing materials, samples and printing.

General and administrative expenses for the three months ended March 31, 2014 were $1.65 million, reflecting an increase of $216,000 or 15%, compared to $1.43 million for the same period in 2013. The increase is primarily attributable to an increase in consulting fees for investor relations, as well as increased professional accounting fees and corporate governance costs.

During the first quarter of 2014, we have raised $1.1 million of capital through our equity line with Lincoln Park Capital, LLC.

Conference call details:
Date: Wednesday, May 14, 2014
Time: 11:00 a.m. Eastern Time
Conference Number (U.S.): 1-877-941-2069
International Dial-In: 1-480-629-9713
Conference ID: 4682485
Webcast: http://public.viavid.com/confirmation/confirmwebcast.php?id=o5aroJyX

Please dial in at least 10 minutes before the call to ensure timely participation.

A playback of the call will be available from 05/14/14 at 5:00 pm ET until 05/28/14 at 11:59 pm ET. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin number 4682485.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-looking Statements
Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

                                                                            
                                                                            
            International Stem Cell Corporation and Subsidiaries            
                   Condensed Consolidated Balance Sheets                    
                     (in thousands, except share data)                      
                                                                            
                                                                            
                                                March 31,     December 31,  
                                                  2014            2013      
                                                                            
Assets                                                                      
  Cash and cash equivalents                  $          991  $        2,243 
  Accounts receivable, net of allowance for                                 
   doubtful accounts of $19 at March 31,                                    
   2014 and December 31, 2013                           501             306 
  Inventory, net                                      1,357           1,369 
  Prepaid expenses and other current assets             636             658 
  Restricted cash                                        50              50 
                                                                            
    Total current assets                              3,535           4,626 
  Property and equipment, net                           742             830 
  Intangible assets, net                              2,342           2,250 
  Deposits and other assets                              33              33 
                                                                            
    Total assets                             $        6,652  $        7,739 
                                             ==============  ============== 
                                                                            
Liabilities, Redeemable Preferred Stock and                                 
 Stockholders' Deficit                                                      
  Accounts payable                           $          518  $          532 
  Accrued liabilities                                   952           1,290 
  Deferred revenue                                       --               3 
  Related party payable                                  26              21 
  Advances                                              250             250 
  Fair value of warrant liability                     4,302           4,925 
                                                                            
    Total current liabilities                         6,048           7,021 
                                                                            
Convertible Redeemable Series G Preferred                                   
 stock, $0.001 par value, 5,000,000 shares                                  
 authorized, issued and outstanding at March                                
 31, 2014 and December 31, 2013, liquidation                                
 preference of $5,000 at March 31, 2014 and                                 
 December 31, 2013                                    4,941           4,941 
                                                                            
Commitments and contingencies                                               
                                                                            
Stockholders' Deficit                                                       
Series D Preferred stock, $0.001 par value,                                 
 50 shares authorized, 43 issued and                                        
 outstanding at March 31, 2014 and December                                 
 31, 2013, with liquidation preference of                                   
 $4,320 at March 31, 2014 and December 31,                                  
 2013                                                    --              -- 
Series B Preferred stock, $0.001 par value,                                 
 5,000,000 shares authorized, 300,000 issued                                
 and outstanding at March 31, 2014 and                                      
 December 31, 2013, with liquidation                                        
 preferences of $408 and $403 at March 31,                                  
 2014 and December 31, 2013, respectively                --              -- 
Common stock, $0.001 par value, 300,000,000                                 
 shares authorized, 156,904,553 and                                         
 151,175,053 issued and outstanding at March                                
 31, 2014 and December 31, 2013,                                            
 respectively                                           157             151 
Additional paid-in capital                           79,212          77,897 
Accumulated deficit                                 (83,706)        (82,271)
                                                                            
  Total stockholders' deficit                        (4,337)         (4,223)
                                                                            
  Total liabilities, redeemable preferred                                   
   stock and stockholders' deficit           $        6,652  $        7,739 
                                             ==============  ============== 
                                                                            
                                                                            
                                                                            
                                                                            
            International Stem Cell Corporation and Subsidiaries            
              Condensed Consolidated Statements of Operations               
                   (in thousands, except per share data)                    
                                (Unaudited)                                 
                                                                            
                                                                            
                                                   Three Months Ended       
                                                        March 31,           
                                                  2014            2013      
Revenues                                                                    
  Product sales                              $        1,649  $        1,285 
                                                                            
    Total revenue                                     1,649           1,285 
                                                                            
Expenses                                                                    
  Cost of sales                                         439             334 
  Research and development                              958             721 
  Selling and marketing                                 669             511 
  General and administrative                          1,648           1,432 
                                                                            
  Total expenses                                      3,714           2,998 
                                                                            
Loss from operating activities                       (2,065)         (1,713)
                                                                            
Other income (expense)                                                      
  Change in fair value of warrant liability             623              -- 
  Miscellaneous expense                                  --              (2)
  Interest expense                                       (1)             (1)
  Sublease income                                         8               4 
                                                                            
    Total other income (expense), net                   630               1 
                                                                            
Loss before income taxes                             (1,435)         (1,712)
Provision for income taxes                               --              -- 
                                                                            
  Net loss                                   $       (1,435) $       (1,712)
                                             ==============  ============== 
                                                                            
Net loss applicable to common stockholders   $       (1,435) $       (1,712)
                                             ==============  ============== 
                                                                            
Net loss per common share-basic and diluted  $        (0.01) $        (0.02)
                                             ==============  ============== 
                                                                            
Weighted average shares-basic and diluted           153,488         103,566 
                                             ==============  ============== 
                                                                            
                                                                            

Contacts:
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383
Email: ir@intlstemcell.com

Mr. Jay Novak
Chief Financial Officer
Phone: 760-940-6383
Email: jnovak@intlstemcell.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES